Overview
Rezolute fiscal Q1 net loss widens to $18.2 mln from $15.4 mln a year ago
Operating expenses for fiscal Q1 rise to $19.8 mln from $16.9 mln last year
Result Drivers
R&D EXPENSES - Increase in R&D expenses due to higher clinical trial activities and employee-related costs
G&A EXPENSES - Rise in G&A expenses attributed to professional fees and increased headcount
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$18.15 mln
Q1 Income From Operations
-$19.82 mln
Q1 Operating Expenses
$19.82 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Rezolute Inc is $14.00, about 33.2% above its November 5 closing price of $9.35
Press Release: ID:nGNX62nfyK
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
